The story begins with microglia, the resident immune cells of the central nervous system. Under healthy conditions, microglia patrol the spinal cord and support tissue repair. After a nerve injury, however, many of them flip into a pro-inflammatory state, pumping out signaling molecules such as tumor necrosis factor, interleukin-6, and interleukin-1β that amplify pain signals. The researchers behind the new study, working with a mouse model of spared nerve injury, showed that this polarization shift is a central pathological node in neuropathic pain—and that coaxing microglia back toward an anti-inflammatory, pro-repair state can meaningfully relieve hypersensitivity to both mechanical touch and cold.

Their therapeutic tool of choice was aspirin-triggered resolvin D1, or AT-RvD1, a member of the specialized pro-resolving mediators. These are not conventional anti-inflammatory drugs that simply suppress the immune response; they are lipid messengers derived from omega-3 fatty acids that actively terminate inflammation and restore tissue homeostasis. AT-RvD1 itself is a 17R-hydroxylated derivative of docosahexaenoic acid, produced in the body when aspirin-acetylated cyclooxygenase-2 reroutes DHA metabolism toward resolution. Earlier work had hinted that AT-RvD1 could calm neuroinflammation in the spinal dorsal horn, but the molecular machinery it engaged remained obscure, and the molecule’s clinical promise was hobbled by rapid degradation in the bloodstream and the invasiveness of direct spinal injection.

To find the missing mechanism, the team turned to computational and molecular detective work. Mining a publicly available gene-expression dataset from a spinal nerve ligation model, they identified angiopoietin-like protein 4, or ANGPTL4, as a gene sharply upregulated in injured spinal cords. Subsequent experiments in BV2 microglial cells confirmed the pattern: inflammatory stimulation with lipopolysaccharide drove ANGPTL4 expression upward, and AT-RvD1 pulled it back down. The functional stakes became clear when the researchers manipulated ANGPTL4 directly. Silencing it with small interfering RNA suppressed pro-inflammatory cytokines, while overexpressing it—either in cultured cells or via adeno-associated virus in injured mice—fanned the inflammatory flames, pushed microglia toward the pro-inflammatory CD86-positive state, and blunted AT-RvD1’s analgesic effects. ANGPTL4, in short, was a linchpin.

The next question was how ANGPTL4 exerts its influence. Quantitative proteomics of treated microglia pointed the investigators toward propionate metabolism, and gas chromatography–mass spectrometry revealed that AT-RvD1 significantly raised propionate concentrations in the injured spinal cord. Immunoprecipitation coupled with mass spectrometry then identified SUCLG1, a key enzyme of the tricarboxylic acid cycle and propionate metabolism, as a physical binding partner of ANGPTL4. Co-immunoprecipitation and confocal imaging confirmed the interaction, and molecular docking revealed specific hydrogen bonds between the two proteins. The picture that emerged was elegant: ANGPTL4 binds SUCLG1 and shields it from ubiquitin-proteasome degradation, keeping the enzyme abundant. When AT-RvD1 suppresses ANGPTL4, SUCLG1 loses its protector, becomes polyubiquitinated, and is dismantled by the proteasome—shifting the spinal metabolic environment toward higher propionate, which the team showed is itself anti-inflammatory.

The metabolic logic checked out in both directions. Adding sodium propionate to AT-RvD1 treatment suppressed inflammatory proteins in microglia more strongly than the resolvin alone, and in injured mice the combination further reduced spinal inflammation and eased mechanical and cold allodynia. In a Transwell co-culture system pairing microglia with HT22 neurons, AT-RvD1-treated microglia passed along less inflammatory signaling to their neuronal neighbors, an effect amplified by propionate. The researchers had, in effect, charted a complete signaling axis—AT-RvD1 to ANGPTL4 to SUCLG1 to propionate—linking a lipid mediator of resolution to a metabolic switch that reprograms immune cells in the pain-processing centers of the spinal cord.

But a mechanism is only half a therapy. AT-RvD1 is fragile, degraded quickly in vivo, and getting it into the spinal cord conventionally requires intrathecal injection—a highly invasive procedure unsuited to repeated long-term dosing. The team’s solution was a liposomal nanocarrier decorated with MG1, a peptide that selectively recognizes activated microglia. Built from soy phosphatidylcholine, cholesterol, and a PEGylated lipid conjugated to the peptide, the resulting particles, dubbed A@Lipo-MG1, measured roughly 71 nanometers in diameter with a strongly negative surface charge, uniform size distribution, and spherical morphology confirmed by transmission electron microscopy. Nuclear magnetic resonance verified the peptide conjugation, and release studies showed a controlled profile, with more than half of the encapsulated AT-RvD1 released over four hours.

The targeting performance was striking. In cultured BV2 cells, rhodamine-labeled MG1-modified liposomes were taken up far more efficiently than unmodified versions, and the particles dampened inflammatory protein expression in a dose-dependent manner. In a laboratory model of the blood–spinal cord barrier, the modified liposomes crossed more readily, and pre-blocking with free MG1 peptide erased the advantage—strong evidence that the peptide was doing the recognition work. In injured mice, intravenously injected IR780-labeled MG1 liposomes lit up the spinal cord at six and twenty-four hours far more brightly than unmodified carriers, and confocal microscopy showed the fluorescent cargo accumulating inside Iba1-positive microglia in the spinal dorsal horn. Liquid chromatography–tandem mass spectrometry confirmed that A@Lipo-MG1 delivered the highest spinal AT-RvD1 concentrations of any formulation tested.

Functionally, the payoff was decisive. Intravenous free AT-RvD1 produced only a minimal analgesic effect, but the targeted liposomal formulation significantly alleviated mechanical hypersensitivity in the nerve-injured mice while reducing spinal mRNA and protein levels of interleukin-6, interleukin-1β, and tumor necrosis factor. Safety profiling showed no abnormalities in liver or kidney function biomarkers, and histological examination of heart, liver, spleen, lung, and kidney revealed no structural damage or inflammatory infiltration. The authors are candid about limitations: they did not resolve exactly how ANGPTL4 inhibits SUCLG1 ubiquitination, the precise binding interface remains unmapped, and only male mice were studied, leaving sex-dependent effects unexplored. Long-term pharmacokinetics in larger animals also await testing.

Even with those caveats, the study lands at a compelling intersection of immunology, metabolism, and nanomedicine. It elevates ANGPTL4 from a lipid-metabolism curiosity to a druggable node in spinal neuroinflammation, ties microglial polarization to a concrete metabolic handle in propionate, and demonstrates that a rationally designed, peptide-targeted liposome can ferry an unstable resolution mediator across biological barriers to the exact cells that need it. For the millions of patients whose pain outlasts their injuries and resists conventional drugs, the prospect of an intravenous therapy that does not merely mute pain signals but actively resolves the inflammation driving them is a genuinely new chapter—one that now has a defined molecular axis, a workable delivery vehicle, and a clear path toward translational testing.

Subject of Research: Targeted liposomal delivery of aspirin-triggered resolvin D1 to reprogram spinal microglia via the ANGPTL4-SUCLG1-propionate axis for neuropathic pain treatment

Article Title: AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain

Article References: Wu, K., Gao, C., Fu, S., Li, Y., Li, Z., Han, X., Zhang, Y., Zhang, Y., & Wang, Y. (2026). AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain. Materials Today Bio, 41, Article 103726. https://doi.org/10.1016/j.mtbio.2026.103726

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103726

Keywords: neuropathic pain, microglia, AT-RvD1, specialized pro-resolving mediators, ANGPTL4, SUCLG1, propionate, liposomes, nanomedicine, neuroinflammation, drug delivery, spinal cord

The research began with a deliberately focused starting point: lipid metabolism. Metabolic dysfunction sits at the heart of diabetes, and bioactive lipid mediators are known to shape skin inflammation and immunity, so the team reasoned that genes tied to lipid handling might yield clues about why diabetic wounds fail to close. Using public gene expression data deposited in the Gene Expression Omnibus under accession numbers GSE80178, GSE68183, GSE134431, GSE199939 and GSE223964, the investigators first identified differentially expressed genes between diabetic ulcer samples and non-ulcer controls, then intersected those changes with curated lipid metabolism-related gene sets drawn from the Molecular Signatures Database.

From that intersection, the researchers deployed a random forest machine learning model, an ensemble method that builds many decision trees on random subsets of the data and votes on the most informative features. The algorithm whittled the candidate list down to a compact panel of ten genes: ANGPTL4, BNIP3, EEF2K, EIF4EBP1, KLHDC1, KLK10, KLK8, NFIX, QSOX1 and S100A8. When the model’s performance was evaluated with receiver operating characteristic analysis, the ten-gene panel showed strong discrimination between ulcer and non-ulcer tissue, and its expression patterns proved reproducible across external validation cohorts that the model had never seen during training.

Each member of the panel carries biological weight in the context of wound repair. ANGPTL4, an angiopoietin-like protein, has been implicated in fibrotic progression in diabetic kidney disease and acts as a regulator of lipid metabolism during systemic inflammation. BNIP3 is a mitochondrial receptor that triggers mitophagy, the selective disposal of damaged mitochondria, a process increasingly recognized as a checkpoint of immune function. EEF2K and EIF4EBP1 sit on pathways governing protein synthesis and the mechanistic target of rapamycin complex 1, a nutrient-sensing hub. KLK8 and KLK10 belong to the kallikrein family of secreted proteases, NFIX is a transcription factor, QSOX1 participates in extracellular matrix maturation through hydrogen peroxide production, and S100A8 is a well-characterized alarmin released during inflammatory responses.

To understand what the signature means immunologically, the team applied single-sample gene set enrichment analysis, gene set enrichment analysis, and gene set variation analysis to the transcriptomic data. These techniques estimate the activity of predefined biological pathways within each individual sample rather than averaging across groups. The analyses linked the ten-gene panel to infiltration by T helper 17 cells, a pro-inflammatory CD4 T cell subset defined by production of interleukin 17A, and to interleukin receptor activity. The connection is biologically plausible: previous work has shown that suppressing Th17 cell differentiation can promote diabetic chronic wound healing, and pro-inflammatory cytokines such as interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha are established contributors to impaired repair in diabetic skin.

Single-cell RNA sequencing added a spatial and cellular dimension to the findings. By profiling gene expression in individual cells recovered from wound tissue, the researchers localized the panel genes to distinct wound-associated cell populations, showing that the signature is not a diffuse tissue-level signal but a composite of specific cell types responding to the diabetic wound environment. This cell-specific attribution matters for interpretation, because a gene that appears elevated in bulk tissue may reflect a shift in cellular composition rather than a change in per-cell expression, and disentangling the two is essential for choosing the right therapeutic target.

The computational work was then stress-tested in living animals. The team induced diabetes in C57BL/6 mice with streptozotocin, a chemical that destroys insulin-producing beta cells, and created standardized wounds whose closure was tracked by serial imaging. Diabetic mice exhibited delayed wound closure and greater residual wound widths than non-diabetic control animals, reproducing the clinical phenotype the gene panel is meant to explain. Hematoxylin and eosin staining of wound sections allowed the researchers to assess tissue architecture, while quantitative real-time polymerase chain reaction measured transcript levels of representative genes, enzyme-linked immunosorbent assays quantified secreted protein markers, and western blotting confirmed changes at the protein level. Critically, the transcript and protein assays showed concordant changes, meaning the RNA-level signature translated into measurable molecular differences in the wounded tissue.

Beyond diagnosis, the study explored therapeutic angles through drug-gene interaction analysis using the Drug Gene Interaction Database, which catalogs known relationships between genes and pharmacological compounds. This step flags whether any of the ten biomarkers are already druggable or targeted by existing agents, offering a shortcut from biomarker discovery to repurposing opportunities. The authors also performed single-gene pathway analyses for each hub gene, mapping individual genes onto Kyoto Encyclopedia of Genes and Genomes pathways, and compared pathway activity between high- and low-expression groups for every member of the panel, revealing how each gene’s expression level reshapes the surrounding signaling landscape.

The significance of the work lies in its integration. Biomarker studies often rely on a single dataset and a single method, leaving results vulnerable to batch effects and cohort-specific quirks. By combining differential expression, machine learning feature selection, multiple enrichment frameworks, single-cell resolution, external validation, and an animal model with orthogonal protein-level confirmation, the researchers built a chain of evidence in which each link compensates for the weaknesses of the others. The result is a candidate signature that behaves consistently across human cohorts and mouse wounds, and that points toward a coherent biological story in which lipid metabolic stress, defective mitophagy, and Th17-driven inflammation converge to keep diabetic ulcers open.

The authors are careful to note the limits of the work. The panel remains a candidate biomarker set, and further validation in larger human cohorts is required before any clinical application, whether as a diagnostic test to stratify patients at risk of non-healing or as a guide to anti-inflammatory therapy. Diabetic foot ulcers impose a heavy and unequal burden globally, and a molecular yardstick that captures the immune and metabolic state of a wound could eventually help clinicians decide which lesions need aggressive intervention and which are likely to progress toward closure. For now, the ten-gene panel offers researchers a concrete molecular handle on one of diabetes most stubborn complications, and a template for how machine learning and classical wet-lab validation can be stitched together to interrogate complex disease tissue.

Subject of Research: Identification of candidate biomarkers and immune features in diabetic ulcers through integrative transcriptomic and machine learning analysis

Article Title: Integrative transcriptomic and machine learning analysis identifies candidate biomarkers and immune features in diabetic ulcers

Article References: Jiang, Y., Cai, Y., Liu, Q., Jiang, J., Shen, F., Zhang, Y., Fei, X., Kuai, L., Zhang, Z., Luo, Y., Song, J., Ma, X., Li, B., Ma, X., & Ru, Y. (2026). Integrative transcriptomic and machine learning analysis identifies candidate biomarkers and immune features in diabetic ulcers. Molecular Biology Reports, 53(1), Article 1669. https://doi.org/10.1007/s11033-026-12862-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12862-z

Keywords: diabetic ulcers, biomarkers, machine learning, transcriptomics, lipid metabolism, Th17 cells, single-cell RNA sequencing, wound healing, random forest, immune microenvironment, ANGPTL4, S100A8